查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947975

全球暴露前預防市場（按產品類型、劑型、分銷管道和最終用戶分類）預測（2026-2032年）

Pre-Exposure Prophylaxis Market by Product Type, Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，暴露前預防 (PrEP) 市場價值將達到 19.2 億美元，到 2026 年將成長至 20.4 億美元，複合年成長率為 7.44%，到 2032 年將達到 31.8 億美元。

關鍵市場統計數據
基準年 2025 19.2億美元
預計年份：2026年 20.4億美元
預測年份 2032 31.8億美元
複合年成長率 (%) 7.44%

暴露前預防（PrEP）策略實施：一個涵蓋臨床進展、衛生系統整合和預防優先事項的框架，塑造當代公共衛生應對措施

暴露前預防（PrEP）處於生物醫學創新、公共衛生政策和社區主導的預防工作的關鍵交匯點。過去十年，PrEP已從一項小眾臨床干預措施發展成為公認的愛滋病預防支柱，這得益於大量證據證明，當與持續堅持治療方案和支持性服務相結合時，PrEP具有顯著的有效性。如今，臨床醫生、公共衛生官員和計劃團體不僅關注藥物療效，也關注能夠確保持續獲得​​PrEP的系統，包括定期篩檢、依從性支持和消除歧視的就醫途徑。

分析重塑PrEP服務提供方式的關鍵結構性變化，包括治療方法創新、數位化照護模式以及推動策略重組的競爭壓力

PrEP領域經歷了許多變革，這些變革正同時改變臨床實務和市場行為。藥物多樣化，特別是長效注射劑與口服製劑的臨床應用，擴大了患者和臨床醫生的選擇範圍，並促使人們重新審視用藥依從治療方法模式和給藥基礎設施。同時，學名藥的擴張也帶來了新的競爭動態，影響著籌資策略、價格談判和付款方的議價能力。

重點評估美國關稅變化對供應鏈、分銷系統和支付方決策中預防性治療取得途徑​​的影響。

影響藥品進口和供應鏈的政策和貿易措施直接影響暴露前預防（PrEP）生態系統中的供應、價格波動和製造商決策。關稅調整和進口限制會增加活性藥物成分、輔料和成品物流的營運成本，可能迫使製造商和經銷商重新評估其籌資策略和生產地點。為此，一些製造商可能會加快生產本地化進程或使其供應商網路多元化，以確保供應連續性免受關稅波動的影響。

可操作的細分分析揭示了產品類型、劑量形式、通路選擇和最終用戶環境如何相互作用，從而影響實際的 PrEP 交付和獲取。

細分市場層面的趨勢揭示了臨床偏好、採購選擇和分銷實踐相互交織，共同影響藥物可及性和應用的領域。就產品類型而言，相關人員必須權衡品牌藥的現有地位（例如作為臨床標準的領先口服療法）與學名藥日益成長的市場佔有率（後者正在改變成本結構和購買行為）。在品牌藥產品組合中，即使新的治療方案不斷出現，但某些現有產品仍在影響處方模式。同樣重要的是劑型方面的差異：注射劑需要在診所內給藥，需要低溫運輸管理以及不同的用藥支持模式，而口服藥物則更注重藥房供應和患者自我管理。

從區域比較觀點，探討法規結構、健康系統能力和社區參與如何驅動全球不同的暴露前預防（PrEP）採用模式。

法規環境、醫療基礎設施和社會因素的區域差異導致全球市場中暴露前預防（PrEP）的採納和使用模式各不相同。在美洲，公共衛生計畫和社區組織在擴大預防服務的覆蓋範圍和提高其使用率方面發揮了核心作用，但服務集中在都市區與需要將服務覆蓋範圍擴展到農村和醫療服務不足地區之間存在著明顯的矛盾。歐洲、中東和非洲（EMEA）地區的許多國家有著截然不同的監管路徑和資金籌措機制。這種多樣性影響著產品的可及性、學名藥在公共採購中的作用，以及醫療系統支持以診所或社區為基礎的服務模式的能力。

簡要概述產業競爭動態，重點介紹製造商、經銷商和服務提供者影響競爭的策略措施。

製造商、經銷商和服務提供者之間的競爭動態正在塑造預防產品組合和商業策略的未來發展方向。現有製藥公司持續投資於核心產品的生命週期管理，並推動下一代製劑的研發，以鞏固其治療優勢。新參與企業和非專利生產商加劇了價格競爭，並擴大了處方箋選擇範圍，這促使現有企業透過療效數據、患者援助計劃以及與支付方和診所的合作來尋求差異化競爭。

為產業領導者提供策略性和可操作性的建議，以保障預防性療法的可近性、最佳化交付模式並促進其公平普及。

對於希望提升專案成效的領導者，我們建議採取一系列協調一致的舉措，同時改善供應、獲取途徑和病患體驗。首先，應實現採購和生產策略多元化，減少對單一國家的依賴以及關稅帶來的成本壓力，並在條件允許的情況下投資國內或區域生產。其次，應根據不同的醫療環境調整產品系列，使產品組合與供給能力相符。例如，應優先發展診所計畫並加強長效注射劑的培訓，同時確保最佳化口服療法的藥房管道。

我們採用透明、穩健的混合方法調查方法，結合相關人員訪談、政策分析和供應鏈情境映射，得出策略意義。

我們的研究方法融合了定性和定量技術，旨在建立全面的證據基礎，同時也認知到其固有的局限性。主要研究包括對臨床研究人員、感染疾病專家、採購負責人、支付者和患者權益倡導團體進行深入訪談，以了解他們對臨床應用、供應鏈限制和患者偏好的實地觀點。次要研究資料包括監管指南、臨床試驗論文和政策文件，用於檢驗臨床特徵和核准時間表。我們對這些資訊進行了三角驗證，以確保其一致性並突出不同相關人員之間的差異。

簡明扼要的結論整合了臨床進展、系統準備和政策槓桿，這些因素決定了預防策略的公平影響。

全面的證據表明，預防性醫療保健領域正經歷快速演變，產品創新、服務模式和政策選擇共同決定醫療服務的可近性和公平性。長效製劑和多元化的產品系列拓展了臨床選擇，但其影響取決於醫療系統的準備情況、支付方的合作以及針對最需要幫助人群的精準推廣。受學名藥和貿易政策影響的成本趨勢將影響採購決策和公共專案的永續性，進一步凸顯了積極主動的供應鏈管理和策略性支付方參與的必要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的暴露前預防市場

  • 品牌產品
    • 德斯科比
    • Truvada
  • 學名藥

9. 按劑型分類的暴露前預防市場

  • 注射
  • 口服

第10章 按分銷管道分類的暴露前預防市場

  • 網路藥房
  • 線下藥房

第11章 按最終用戶分類的暴露前預防市場

  • 診所
  • 居家照護
  • 醫院

第12章 各地區的暴露前預防市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的暴露前預防市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國暴露前預防市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國暴露前預防市場

第16章：中國的暴露前預防藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6B9

The Pre-Exposure Prophylaxis Market was valued at USD 1.92 billion in 2025 and is projected to grow to USD 2.04 billion in 2026, with a CAGR of 7.44%, reaching USD 3.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.92 billion
Estimated Year [2026] USD 2.04 billion
Forecast Year [2032] USD 3.18 billion
CAGR (%) 7.44%

A strategic introduction to Pre-Exposure Prophylaxis that frames clinical advances, health system integration, and prevention priorities shaping modern public health responses

Pre-exposure prophylaxis (PrEP) sits at a pivotal intersection of biomedical innovation, public health policy, and community-led prevention. Over the last decade, PrEP shifted from a niche clinical intervention to a widely recognized pillar of HIV prevention, driven by robust evidence demonstrating efficacy when regimens are taken consistently and paired with supportive services. Clinicians, public health authorities, and advocacy groups now emphasize not only pharmacologic effectiveness but also the systems that enable sustained access, including routine screening, adherence support, and destigmatized care pathways.

Consequently, programmatic attention has expanded beyond clinical trials to real-world implementation: integration into primary care, targeted outreach to populations at highest risk, and the development of differentiated service delivery models. Advances in biomedical options, such as long-acting injectables alongside established oral regimens, are reshaping clinical algorithms and patient preferences. At the same time, regulatory decisions, payer policies, and supply chain dynamics influence the pace and equity of uptake. For stakeholders, the imperative is clear: design prevention strategies that marry clinical efficacy with scalable, sustainable delivery models that reach marginalized and geographically dispersed populations.

An analysis of the major structural shifts reshaping PrEP delivery including therapeutic innovation, digital care models, and competitive pressures driving strategic realignment

The landscape of PrEP has undergone several transformative shifts that are altering clinical practice and market behavior in tandem. Pharmacologic diversification, most notably the clinical adoption of long-acting injectable agents alongside oral products, has broadened the range of options for patients and clinicians, prompting reexamination of adherence paradigms and delivery infrastructure. Parallel to therapeutic innovation, the expansion of generic formulations has introduced new competitive dynamics that influence procurement strategies, pricing negotiations, and the bargaining power of payers.

Simultaneously, digital health tools and telemedicine have matured into practical enablers of PrEP initiation and follow-up care, allowing remote screening, virtual counseling, and adherence monitoring to link with pharmacy delivery models. Health systems and community-based organizations are increasingly leveraging data-driven outreach and combination prevention approaches to identify and engage underserved groups. As regulatory frameworks evolve to accommodate novel formulations and prescribing models, stakeholders must adapt contracting, training, and distribution systems. Taken together, these shifts necessitate integrated planning across clinical, commercial, and policy domains to translate scientific progress into equitable public health gains.

A focused evaluation of how tariff changes in the United States can cascade through supply chains, distribution systems, and payer decisions to affect access to prevention therapies

Policy and trade actions affecting pharmaceutical imports and supply chains exert a proximal influence on availability, pricing dynamics, and manufacturer decision-making in the PrEP ecosystem. Tariff adjustments and import restrictions can increase the operational cost of active pharmaceutical ingredients, excipients, and finished product logistics, which in turn can prompt manufacturers and distributors to reevaluate sourcing strategies and production footprints. In response, several manufacturers may accelerate localization of manufacturing or diversify supplier networks to insulate supply continuity from tariff volatility.

Beyond manufacturing, tariff-related cost pressures can ripple through distribution channels, influencing inventory strategies at hospital and retail pharmacies as well as online fulfillment arrangements. Payers and health systems may respond by prioritizing procurement of lower-cost generic alternatives or by renegotiating contracts to preserve patient access. Meanwhile, regulatory agencies and advocacy groups often intensify efforts to mitigate access disruptions through streamlined approvals for alternative sources and collaborative procurement mechanisms. Ultimately, tariff policy is one of multiple levers that can reshape the economics of prevention programs; prudent stakeholders will assess tariff exposure, pursue supply diversification, and engage policymakers to protect affordability and continuity of care.

An actionable segmentation analysis revealing how product type, formulation, channel choices, and end-user settings converge to shape practical PrEP delivery and access

Segment-level dynamics illuminate where clinical preferences, procurement choices, and distribution practices intersect to influence access and uptake. In the context of product type, stakeholders must balance the established role of branded options-such as leading oral regimens that have served as clinical standards-with the growing presence of generic alternatives that alter cost structures and purchasing behavior; within branded portfolios, specific legacy products continue to shape prescribing patterns even as newer options enter practice. Form-related distinctions are equally consequential: injectable formulations demand clinic-based administration, cold-chain management, and different adherence support models compared with oral regimens, which emphasize pharmacy access and patient-managed dosing.

Distribution channel segmentation highlights operational and strategic trade-offs. Hospital pharmacies offer integrated clinical oversight and linkage to specialty care, while retail pharmacies provide convenient access for episodic refills and broad geographic reach; online pharmacies expand reach further but require robust verification and fulfillment capabilities. End-user settings create divergent service delivery models: clinics can deliver comprehensive counseling and laboratory monitoring, home care models can support adherence through remote monitoring and delivery services, and hospitals often manage initiation for more medically complex patients. Synthesizing these segment insights, effective strategies prioritize product-form fit to delivery capacity, align procurement with payer preferences, and design patient-centered pathways that leverage the strengths of each channel and end-user environment.

A comparative regional perspective that maps how regulatory frameworks, health system capacity, and community engagement drive divergent PrEP adoption patterns globally

Regional variability in regulatory environments, health infrastructure, and social determinants drives distinct patterns of PrEP deployment and uptake across global markets. In the Americas, national public health programs and community organizations have been central to expanding access and normalizing prevention services, with urban concentration of services contrasted by the need to extend reach to rural and underserved communities. In many countries within Europe, Middle East & Africa, regulatory pathways and financing mechanisms vary widely; this heterogeneity affects the timing of product availability, the role of generics in public procurement, and the capacity of health systems to support clinic-based or community-delivered models.

Across the Asia-Pacific region, a mixture of advanced healthcare systems and resource-constrained environments creates a patchwork of adoption scenarios. Some economies rapidly incorporate novel long-acting agents into practice where regulatory approvals and payer coverage align, while other markets rely heavily on generic oral options and targeted pilot programs. Cross-region collaborations, knowledge exchange, and pooled procurement initiatives increasingly offer mechanisms to address disparities, but success depends on tailoring strategies to local delivery realities, cultural contexts, and the robustness of laboratory and monitoring infrastructure.

A concise synthesis of industry competitive dynamics highlighting strategic maneuvers by manufacturers, distributors, and service providers that affect access and positioning

Competitive dynamics among manufacturers, distributors, and service providers are shaping the future direction of prevention portfolios and commercial strategies. Established pharmaceutical companies continue to invest in lifecycle management for core products while advancing next-generation formulations to defend therapeutic franchises. New market entrants and generic manufacturers intensify price competition and expand formulary options, prompting incumbent firms to differentiate through outcomes data, patient support programs, and partnerships with payers and clinics.

Strategic collaborations between pharmaceutical companies and contract manufacturers have become more prevalent as firms seek to scale production, manage cost exposure, and ensure supply chain redundancy. Additionally, alliances with digital health companies and specialty pharmacies enable integrated care pathways that improve adherence and retention. For decision-makers, the key implication is that competitive positioning increasingly depends on combined clinical evidence, service delivery capability, and the ability to demonstrate value to payers and providers in routine practice.

Strategic and implementable recommendations for industry leaders designed to protect access, optimize delivery models, and accelerate equitable uptake of prevention therapies

Leaders seeking to strengthen program impact should pursue a set of coordinated actions that address supply, access, and patient experience simultaneously. First, diversify sourcing and manufacturing strategies to reduce exposure to single-country supply disruptions and tariff-induced cost pressures, while investing in onshore or regional production where feasible. Second, align product portfolios with delivery capabilities by matching formulation choices to care settings; for example, prioritize clinic-based programs and training for long-acting injectables while ensuring pharmacy channels are optimized for oral regimens.

Third, engage payers and policymakers proactively to secure coverage pathways and enable innovative contracting arrangements that support equity-driven access. Fourth, invest in digital adherence tools, telehealth-enabled initiation pathways, and community-led outreach to lower barriers for underserved populations. Finally, measure outcomes through rigorous real-world evidence collection and use those insights to refine clinical guidelines, reimbursement negotiations, and programmatic priorities. By coordinating these actions, organizations can translate product-level advances into durable public health outcomes.

A transparent and robust mixed-methods research methodology that combines stakeholder interviews, policy analysis, and supply chain scenario mapping to derive strategic implications

The research approach integrates qualitative and quantitative techniques to construct a comprehensive evidence base while acknowledging inherent limitations. Primary research consisted of in-depth interviews with clinical investigators, infectious disease specialists, procurement officers, payers, and patient advocates to capture frontline perspectives on clinical adoption, supply chain constraints, and patient preferences. Secondary sources included regulatory guidance, clinical trial publications, and policy documents to verify clinical characteristics and approval timelines. Triangulation across these inputs ensured consistency and helped surface divergent stakeholder views.

Supply chain mapping and scenario analysis were used to evaluate exposure to trade policy shifts and to identify possible mitigation strategies. The methodology prioritized transparency in assumptions, and analytic findings were validated through peer review with external experts where possible. Limitations include the evolving nature of approvals and payer policy decisions; therefore, the analysis emphasizes structural trends and strategic implications rather than transient market estimations, and readers are advised to consider local regulatory announcements and procurement cycles when applying insights.

A concise conclusion synthesizing clinical advances, system readiness, and policy levers that together determine the equitable impact of prevention strategies

The collective evidence points to a rapidly evolving prevention landscape where product innovation, delivery models, and policy choices jointly determine the trajectory of access and equity. Long-acting formulations and diversified product portfolios expand clinical options, but their impact will depend on health system readiness, payer alignment, and targeted outreach to populations with the highest unmet need. Cost dynamics, influenced by generic competition and trade policy, will shape procurement decisions and the sustainability of public programs, reinforcing the need for proactive supply chain management and strategic payer engagement.

Looking ahead, successful stakeholders will be those that translate clinical efficacy into practical delivery by integrating service delivery redesign, digital tools, and community partnerships. By focusing on equitable access, resilience against policy shocks, and evidence-driven engagement with payers and providers, organizations can maximize the public health benefits of prevention innovations while maintaining commercial viability and ethical stewardship of resources.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pre-Exposure Prophylaxis Market, by Product Type

  • 8.1. Branded
    • 8.1.1. Descovy
    • 8.1.2. Truvada
  • 8.2. Generic

9. Pre-Exposure Prophylaxis Market, by Form

  • 9.1. Injectable
  • 9.2. Oral

10. Pre-Exposure Prophylaxis Market, by Distribution Channel

  • 10.1. Online Pharmacies
  • 10.2. Offline Pharmacies

11. Pre-Exposure Prophylaxis Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Pre-Exposure Prophylaxis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pre-Exposure Prophylaxis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pre-Exposure Prophylaxis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pre-Exposure Prophylaxis Market

16. China Pre-Exposure Prophylaxis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accord Healthcare Inc.
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Aurobindo Pharma Ltd.
  • 17.8. Cipla Ltd.
  • 17.9. Dr. Reddy's Laboratories Ltd.
  • 17.10. Fresenius Kabi AG
  • 17.11. Gilead Sciences, Inc.
  • 17.12. Hetero Labs Limited
  • 17.13. Lupin Limited
  • 17.14. Merck & Co., Inc.
  • 17.15. Mylan N.V.
  • 17.16. Sun Pharmaceutical Industries Ltd.
  • 17.17. Teva Pharmaceutical Industries Ltd.
  • 17.18. Viatris Inc.
  • 17.19. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DESCOVY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DESCOVY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DESCOVY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY TRUVADA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY TRUVADA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY TRUVADA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 99. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 100. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GCC PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 117. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 118. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. G7 PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 123. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 124. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. NATO PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)